iClusion thanks HAGA hospital (The Hague, Netherlands) and Novartis Oncology Netherlands for their selfless support in prototyping the iClusion platform.
Today around 5% of cancer patients participate in clinical trials, whereas 50% to 80% wants to participate as indicated by market research. iClusion aspires to increase the participation of cancer patients in clinical trials from 5% to 25% by increasing their accessibility to innovative treatments and chances for better outcomes.
iClusion may dramatically shorten the completion of patient recruitment by increasing recruitment rates and allowing immediate enrolment. The iClusion platform connects patients, oncologists, sponsors and sites, while study start-up procedures have already been implemented compliant with regulatory requirements.